Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].
CAS Nummer:
[2415933-40-1]
Target-Kategorie:
SARS-CoV
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten